Puma Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Puma Biotechnology disminuyan a un ritmo anual de 0.1% y 53.5% respectivamente, mientras que se espera que el BPA disminuya un 54.3% por año.

Información clave

-53.5%

Tasa de crecimiento de los beneficios

-54.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.5%
Tasa de crecimiento de los ingresos	-0.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PBYI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	240	7	42	51	2
12/31/2025	233	14	47	43	2
12/31/2024	231	13	46	40	2
12/31/2023	236	22	14	27	N/A
9/30/2023	229	4	5	24	N/A
6/30/2023	230	-2	11	31	N/A
3/31/2023	235	5	-6	14	N/A
12/31/2022	228	0	-23	-16	N/A
9/30/2022	218	10	-29	-29	N/A
6/30/2022	207	-34	-36	-36	N/A
3/31/2022	201	-49	-22	-22	N/A
12/31/2021	253	-29	21	21	N/A
9/30/2021	250	-48	20	20	N/A
6/30/2021	255	-35	12	12	N/A
3/31/2021	272	-27	18	28	N/A
12/31/2020	225	-60	-9	1	N/A
9/30/2020	235	-56	-2	8	N/A
6/30/2020	241	-42	-11	-1	N/A
3/31/2020	224	-82	27	27	N/A
12/31/2019	272	-76	22	22	N/A
9/30/2019	280	-95	28	28	N/A
6/30/2019	287	-92	28	28	N/A
3/31/2019	284	-99	-35	-34	N/A
12/31/2018	251	-114	-25	-24	N/A
9/30/2018	202	-147	-117	-67	N/A
6/30/2018	145	-210	-165	-114	N/A
3/31/2018	94	-243	-193	-143	N/A
12/31/2017	28	-292	-223	-172	N/A
9/30/2017	6	-301	N/A	-178	N/A
6/30/2017	N/A	-289	N/A	-158	N/A
3/31/2017	N/A	-278	N/A	-143	N/A
12/31/2016	N/A	-276	N/A	-142	N/A
9/30/2016	N/A	-265	N/A	-134	N/A
6/30/2016	N/A	-260	N/A	-136	N/A
3/31/2016	N/A	-258	N/A	-139	N/A
12/31/2015	N/A	-239	N/A	-154	N/A
9/30/2015	N/A	-225	N/A	-140	N/A
6/30/2015	N/A	-200	N/A	-127	N/A
3/31/2015	N/A	-175	N/A	-110	N/A
12/31/2014	N/A	-142	N/A	-77	N/A
9/30/2014	N/A	-110	N/A	-72	N/A
6/30/2014	N/A	-89	N/A	-60	N/A
3/31/2014	N/A	-63	N/A	-54	N/A
12/31/2013	N/A	-55	N/A	-55	N/A
9/30/2013	N/A	-61	N/A	-66	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años (-53.5% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años (-53.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de PBYI disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de PBYI disminuyan en los próximos 3 años (-0.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de PBYI disminuyan en los próximos 3 años (-0.1% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PBYI se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Puma Biotechnology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 45%, revenue downgraded

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Consensus EPS estimates increase by 32%, revenue downgraded

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

Recent updates

Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates increase by 45%, revenue downgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Founder notifies of intention to sell stock

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$71k worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Founder recently sold US$114k worth of stock

Founder notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Puma Biotechnology, Inc. announced that it has received $2.499996 million in funding

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

Investor sentiment improved over the past week

Price target decreased to US$5.40

Puma Biotechnology, Inc. Announces Update on Defamation Lawsuit

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated

Puma Biotechnology, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Consensus forecasts updated

Independent Director recently sold US$89k worth of stock

Price target decreased to US$5.40

Price target decreased to US$5.40